Nanosonics Limited (ASX: NAN)
Nanosonics Limited (ASX: NAN) is a health care company which received very pleasing results in FY 2018 with sales of $60.7 million and a pre-tax profit of $5.6 million contributing to a further increase in the cash balance to $69.4 million. The company has maintained a strong and growing cash position while substantially increasing its investment in sales, marketing, service, and operations, which will underpin the companyâs strategic growth plans. During FY 2018, the company delivered a significant milestone by completing the developmental work on trophon2, together with a successful regulatory filing and approval in the last quarter of FY 2018. The company is expecting an expansion of investment in research and development to approximately $13 million in FY19. In addition to its successful launch of trophon2 and a number of related ecosystem products, Companyâs aim is to continue investment in R&D where the company is building a pipeline of new product opportunities with the goal of introducing a range of new products over time commencing with the first by the end of FY20. In the last six months, the share price of the company increased by 26.25 percent as on 12 November 2018, traded at a PE ratio of 170.310x. NANâs shares traded at $3.210 with a market capitalization of circa $980.29 million as on 13 November 2018.Â
Bionomics Limited (ASX: BNO)
During FY 2018, Bionomics Limited (ASX: BNO) progressed with its major programs for neurological and psychiatric disorders and builds a pipeline of innovative therapies based on the companyâs proprietary drug discovery technologies. In FY 2018, the company earned a revenue from continuing operation of $3.95 million which was $18.8 million in FY17. The net loss after tax of the company increased from $6.75 million in FY17 to $25.08 million in FY 2018. As at 30 September 2018, the company was having a cash balance of $16.67 million and net operating cash outflow during the September quarter was $8.25 million. In the last six months, the share price of the company decreased by 73.28 percent as on 9 November 2018. BNOâs shares were placed in a trading halt on 12 November, and it was last traded at $0.155 per share with a market capitalization of $74.85 million.
SomnoMed Limited (ASX: SOM)
In the first quarter of FY 2019, SomnoMed Limited (ASX: SOM) the revenues of the company increased by 14 percent to $14.8 million as compared to the same quarter last year. Overall, the Companyâs core device business showed strong quarterly revenue growth of 19%, with revenues of $13.15 million, while Renew Sleep Solutions (RSS) witnessed a negative growth of 15%, with revenues of just over $1.65 million. The operating cash outflow for Q1 2019 was $5.8 million, due to the continuing funding of the RSS centres. The cash balance at the end of the September quarter was $7 million. The company has informed in its release that the second quarter cash outflow will be significantly reduced, due to the greater demand and sales volume connected to the seasonally stronger December quarter for SOM and RSS. It is expected that the cash balance will be around $7 million level on 31st December 2018. In the last six months, the share price of the company decreased by 45.24 percent as on 9 November 2018. SOMâs shares traded at $1.590 (-1.242% intraday) with a market capitalization of circa $100.15 million as on 13 November 2018.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people.Â Kalkinemedia.comÂ and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.
With the pandemic continuing to affect the globe, healthcare companies are evaluating their lead compounds for COVID-19 treatment. Future revenue for these stocks depends on the probability of launching an approved treatment in the market.